Showing 1 - 8 results of 8 for search 'Özlem Türeci', query time: 0.11s Refine Results
  1. 1
    Racing for a SARS‐CoV‐2 vaccine

    Racing for a SARS‐CoV‐2 vaccine by Özlem Türeci, Uğur Şahin

    Published 2021-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity

    Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity by Tana A. Omokoko, Uli Luxemburger, Shaheer Bardissi, Petra Simon, Magdalena Utsch, Andrea Breitkreuz, Özlem Türeci, Ugur Sahin

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

    Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data by Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J. Mensa, Claudia Lindemann, Shanti Pather

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

    Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody by Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci

    Published 2023-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

    Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine w... by Joel M. Neutel, Rahsan Erdem, Qin Jiang, Kevin Cannon, Helen Stacey, Ryan Newton, Emily Gomme, Wen Li, Federico J. Mensa, Özlem Türeci, Uğur Şahin, Kena A. Swanson, Iona Munjal, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

    Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial by Oyeniyi Diya, Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade

    A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade by Işıl Altıntaş, Kristina B. Nürmberger, Andrea Imle, Anna-Lena Krause, Marike M. van Beuge, Aras Toker, Andreea Ioan-Facsinay, Jordan Blum, Alexander Muik, Frank J. Beurskens, Rob N. de Jong, David P. E. Satijn, Friederike Gieseke, Bart-Jan de Kreuk, Maarten van der Kroef, Sina Fellermeier-Kopf, Tahamtan Ahmadi, Özlem Türeci, Esther C. W. Breij, Uğur Şahin

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects

    Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects by Maria Jure-Kunkel, Christina Yu, Nora Pencheva, Mark Fereshteh, Alexander Muik, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Brandon W Higgs, Jordan M Blum, Saskia M Burm, Vanessa M Spires, Angelica Sette, Sina Fellermeier-Kopf, Andrea Imle, Michela Capello, Kristin Strumane, Theo Plantinga, Craig J Thalhauser, Kristina B Nürmberger, Patricia Garrido Castro, Carol Costa Sa, Bruna de Andrade Pereira

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: